EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 168 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $4,152,000 | -37.5% | 97,755 | -29.4% | 0.04% | -27.9% |
| Q2 2020 | $6,644,000 | -0.9% | 138,486 | -5.0% | 0.06% | +1.7% |
| Q1 2020 | $6,703,000 | -33.5% | 145,757 | -13.2% | 0.06% | 0.0% |
| Q4 2019 | $10,085,000 | +0.9% | 167,863 | -5.0% | 0.06% | +3.4% |
| Q3 2019 | $9,998,000 | -4.7% | 176,747 | -6.2% | 0.06% | +7.4% |
| Q2 2019 | $10,488,000 | +144.1% | 188,368 | +121.4% | 0.05% | +145.5% |
| Q1 2019 | $4,296,000 | +4.2% | 85,092 | -16.8% | 0.02% | -4.3% |
| Q4 2018 | $4,123,000 | -16.2% | 102,333 | +44.2% | 0.02% | 0.0% |
| Q3 2018 | $4,920,000 | +44.9% | 70,960 | +11.6% | 0.02% | +53.3% |
| Q4 2017 | $3,396,000 | -50.4% | 63,577 | -44.7% | 0.02% | -50.0% |
| Q3 2017 | $6,852,000 | +9.8% | 114,897 | +45.2% | 0.03% | +11.1% |
| Q2 2017 | $6,242,000 | +696.2% | 79,121 | +737.5% | 0.03% | +800.0% |
| Q1 2017 | $784,000 | -79.5% | 9,447 | -80.0% | 0.00% | -81.2% |
| Q2 2015 | $3,828,000 | – | 47,340 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JW Asset Management, LLC | 475,755 | $25,068,000 | 24.71% |
| Hudson Executive Capital LP | 971,000 | $51,162,000 | 15.09% |
| Park West Asset Management LLC | 1,051,274 | $55,392,000 | 2.47% |
| U S GLOBAL INVESTORS INC | 19,200 | $1,012,000 | 0.62% |
| Capital Impact Advisors, LLC | 26,317 | $1,387,000 | 0.57% |
| CLARK ESTATES INC/NY | 56,278 | $2,965,000 | 0.47% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 873,131 | $46,005,000 | 0.41% |
| ProQuest Associates IV LLC | 6,777 | $357,000 | 0.41% |
| Granite Investment Partners, LLC | 114,207 | $6,017,000 | 0.40% |
| GLOBEFLEX CAPITAL L P | 30,900 | $1,628,000 | 0.34% |